WATERTOWN, Mass.--(BUSINESS WIRE)--Tarveda Therapeutics®, Inc., a clinical stage biopharmaceutical company discovering and developing a new class of potent and selective precision oncology medicines for the treatment of patients with a wide range of solid tumor malignancies, today announced that Drew Fromkin, President and Chief Executive Officer, will present at the Raymond James Life Sciences and MedTech Conference occurring June 18-19, 2019 in New York City. Tarveda presentation details:
Date: Tuesday, June 18, 2019
Time: 8:00am Eastern Time
Location:
Lotte New York Palace, New York, NY
About Tarveda Therapeutics®, Inc.
Tarveda Therapeutics is a clinical stage biopharmaceutical company that is developing and discovering a new class of potent and selective precision oncology medicines for the treatment of patients with solid tumor malignancies. We are developing our proprietary Pentarin® miniature conjugates to enhance the effectiveness of promising anti-cancer payloads by selectively binding them to desired tumor targets where they accumulate. http://www.tarvedatx.com/
